85 /100
CRITICAL RISK
Score updated Jul 14, 2026

JAGX — Jaguar Health, Inc. Dilution Risk Tracker

Track JAGX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track JAGX — Get alerts when the score changes →

As of July 14, 2026, Jaguar Health, Inc. (JAGX) has a DilutionWatch DilutionScore of 85/100, rated CRITICAL dilution risk. Jaguar Health, Inc. has a market capitalization of $2.33M, 171.35M shares outstanding, 12 institutional holders tracked. Key dilution vectors include 9.6K outstanding warrants, approximately 6 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
85
📊 Float Risk
100
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
43%
🔁 Convertible Conversion 60%
• Major convertible overhang: 457% potential dilution
• Convertible risk score very high (85/100)
💰 Capital Raise 35%
• Low cash runway: 6 months remaining
📉 Score Deterioration 15%
• Score already CRITICAL (85/100) — events likely imminent
🔔 Track JAGX — Get forecast alerts →

💹 Market Data

Market Cap$2.33M
Shares Outstanding171.35M
FloatN/A
Cash$7.28M
Debt$10.77M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 288.5% shares (2026Q1 vs prior)
12 institutional holders · 256.8K shares
#1 UBS Group AG 112.9K shares
#2 GEODE CAPITAL MANAGEMENT, LLC 110.1K shares
#3 HRT FINANCIAL LP 15.2K shares
+ 9 more holders Sign up free to view →

📉 Short Interest

Short Interest73.8K
Days to Cover1.0
% of FloatN/A
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2025
xbrl XBRL CONVERTIBLE Dec 31, 2025
8-K 8K EVENT May 04, 2026
8-K 8K EVENT Apr 21, 2026
4 INSIDER TRANSACTION Mar 12, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for JAGX Shareholders

Jaguar Health, Inc. (JAGX) carries a DilutionScore of 85/100, placing it in the Critical dilution risk tier — the highest category tracked by DilutionWatch. Companies at this level typically have active capital-raising programs, compressed cash runway, or a combination of dilution vectors that together represent meaningful downside risk to share count. As of July 14, 2026, this score reflects real-time data pulled directly from SEC EDGAR filings.

Cash runway is a key watch item: JAGX has approximately 6 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for JAGX in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for JAGX alongside comparable critical-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track JAGX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking JAGX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — CRITICAL Risk

Other CRITICAL dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for JAGX
📊 JAGX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 JAGX Signal Convergence & Dark Pool Activity — StonkWhisper 📄 JAGX Dilution Risk Analysis — Full In-Depth Report

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.